News | July 30, 2025
Vijaya Diagnostic reports Q1 FY26 consolidated PAT at Rs. 38.33 Cr
The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal
The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal
The transaction is expected to close in Q2 FY 2026
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
Branded formulation business continues to perform well across domestic and export markets
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Subscribe To Our Newsletter & Stay Updated
